Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome:

Amanda L Blackmon1, Lauren Pinter-Brown1,2

  • 1Division of Hematology/Oncology, Department of Medicine, University of California, Irvine, Irvine, CA, USA.

Insights

Mogamulizumab offers improved progression-free survival for advanced cutaneous T-cell lymphomas (CTCL) resistant to other treatments. This novel antibody provides a new option for patients with mycosis fungoides (MF) and Sézary syndrome (SS).

Area of Science:

  • Oncology
  • Immunology
  • Dermatology

Background:

  • Advanced cutaneous T-cell lymphomas (CTCL), including mycosis fungoides (MF) and Sézary syndrome (SS), present significant management challenges, especially upon treatment resistance.
  • Existing systemic therapies offer limited disease control, highlighting an unmet need for durable treatment options, particularly in older populations unsuitable for transplantation.

Purpose of the Study:

  • To review the development and FDA approval of mogamulizumab, a CCR4 humanized monoclonal antibody, for relapsed/refractory MF and SS.
  • To evaluate the efficacy and safety of mogamulizumab compared to vorinostat in patients with advanced CTCL.

Main Methods:

  • The MAVORIC study, a Phase III trial, randomized 372 patients with relapsed/refractory MF/SS to receive either mogamulizumab or vorinostat.
  • Progression-free survival (PFS) was the primary endpoint, with secondary endpoints including overall response rate and safety.

Main Results:

  • Mogamulizumab demonstrated a statistically significant improvement in PFS, with a median of 7.7 months compared to 3.1 months for vorinostat (hazard ratio: 0.53, p<0.001).
  • Mogamulizumab was generally well-tolerated, with common adverse events including infusion-related reactions, rash, diarrhea, and fatigue.

Conclusions:

  • Mogamulizumab is an effective and well-tolerated treatment option for patients with relapsed/refractory MF/SS who have failed prior systemic therapy.
  • This novel antibody represents a significant advancement in the long-term management of advanced CTCL, offering improved disease control.